OTCMKTS:CMXC

Cell MedX (CMXC) Stock Price, News & Analysis

$0.04
+0.01 (+30.30%)
(As of 04/24/2024 ET)
Today's Range
$0.04
$0.04
50-Day Range
$0.02
$0.05
52-Week Range
$0.00
$0.93
Volume
10,020 shs
Average Volume
25,978 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CMXC stock logo

About Cell MedX Stock (OTCMKTS:CMXC)

Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is headquartered in Carson City, Nevada.

CMXC Stock Price History

CMXC Stock News Headlines

The best cell phone plans in 2024
Cells, organ systems and ecosystems
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
CMXC Cell MedX Corp.
Cell structure - AQA Microscopes
Cell biology
Cell MedX Corp CMXC
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
The best cheap cell phone plans in 2023
Chemical cells
Chemical cells and fuel cells
The cell membrane
Mitosis and the cell cycle
Cells and Reproduction
Best Cell Phone Plans of 2022
FDA Submission and Corporate Update
Cell MedX names new CEO
See More Headlines
Receive CMXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cell MedX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
OTCMKTS:CMXC
Previous Symbol
NASDAQ:CMXC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Ms. Yanika Silina C.M.A. (Age 46)
    CPA, CFO, Treasurer, Corporate Secretary & Director
    Comp: $30k
  • Mr. David M. Jeffs (Age 54)
    President, CEO & Director

CMXC Stock Analysis - Frequently Asked Questions

How have CMXC shares performed in 2024?

Cell MedX's stock was trading at $0.0220 on January 1st, 2024. Since then, CMXC shares have increased by 95.5% and is now trading at $0.0430.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Cell MedX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cell MedX investors own include Callon Petroleum (CPE), Himax Technologies (HIMX), Remark (MARK), MicroVision (MVIS), Ritter Pharmaceuticals (RTTR), Linn Energy (LINEQ), AudioEye (AEYE), Bank of America (BAC) and Celldex Therapeutics (CLDX).

How do I buy shares of Cell MedX?

Shares of CMXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CMXC) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners